Form 4: Kymera Grants Chief Legal Officer Adams Equity Awards

Kymera Therapeutics, Inc. has granted its Chief Legal Officer, Brian Adams, 4,125 restricted stock units and options to purchase 8,250 shares of common stock, effective March 2, 2026.

Summary

• Brian Adams, Chief Legal Officer of Kymera Therapeutics, Inc., was granted equity awards.
• The awards include 4,125 Restricted Stock Units (RSUs) and options to purchase 8,250 shares of common stock.
• The effective date for these transactions is March 2, 2026.
• The RSUs will vest in four equal annual installments starting March 2, 2026, contingent on continued employment.
• The stock options have an exercise price of $90.1 and will vest in 48 equal monthly installments following March 2, 2026, also contingent on continued employment.
• The options expire on March 1, 2036.
• Following these transactions, Brian Adams beneficially owns 56,625 shares of common stock and 8,250 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at retaining key talent and aligning management incentives with long-term company performance. It's a routine filing, not indicative of major operational changes.

Positives

• Aligns management's interests with long-term shareholder value through equity ownership.
• Serves as a retention mechanism for a key executive, the Chief Legal Officer.
• The grants are part of standard executive compensation practices.

Negatives

• Potential for future dilution of existing shareholders as RSUs vest and options are exercised.

Future Outlook

The grants of RSUs and stock options are subject to future vesting schedules, with RSUs vesting annually over four years and stock options vesting monthly over 48 months, both contingent on Brian Adams' continued employment through each vesting date. The stock options have an expiration date of March 1, 2036.

Industry Context

StockSavvy.ai notes that equity grants to Chief Legal Officers are a standard practice in the biotechnology and pharmaceutical industries, particularly for publicly traded companies like Kymera Therapeutics. Such grants are crucial for attracting and retaining top legal talent, ensuring alignment with corporate governance and regulatory compliance, and incentivizing long-term performance in a highly regulated sector.

Comparison to Industry Standards

• The structure of equity compensation, including a mix of Restricted Stock Units (RSUs) and stock options with multi-year vesting schedules, is consistent with common practices for executive compensation in the U.S. biotechnology sector.
• Companies such as Moderna (MRNA) and BioNTech (BNTX) frequently utilize similar long-term incentive plans for their executive teams to foster retention and align interests with shareholder value.
• The specific number of units granted would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this filing alone does not provide sufficient data for a direct quantitative comparison to specific peer grants.

Related Party Transactions

• The equity grants to Brian Adams, an officer of Kymera Therapeutics, Inc., constitute a related party transaction as they involve compensation provided by the company to a key management personnel.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon vesting and exercise of equity awards. However, the grants are intended to align executive interests with shareholder value creation.
• Employees: May signal stability in executive leadership and standard compensation practices.
• Management: Provides long-term incentives and compensation for the Chief Legal Officer, fostering retention and motivation.

Next Steps

• Continued employment of Brian Adams through vesting dates for RSUs and stock options.
• Future vesting of 4,125 RSUs in four equal annual installments following March 2, 2026.
• Future vesting of 8,250 stock options in forty-eight equal monthly installments following March 2, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of equity grants. While it aligns management incentives with shareholder value, it does not present new information that would fundamentally alter the investment thesis for Kymera Therapeutics, Inc. It is a standard disclosure and does not warrant a change in investment posture based solely on this filing.

Keywords

Kymera Therapeutics, KYMR, Brian Adams, Chief Legal Officer, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, SEC Form 4, Executive Compensation